Marshall Wace’s Elevation Oncology ELEV Stock Holding History

Marshall Wace’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-154,793	Closed	-$57.3K	–	2996
2025 Q2	$57.3K	Buy	+154,793	New	+$51.7K	﹤0.01%	2588
2024 Q3	–	Sell	-37,738	Closed	-$102K	–	2610
2024 Q2	$102K	Sell	37,738 -94,958	-72%	-$358K	﹤0.01%	2396
2024 Q1	$681K	Buy	+132,696	New	+$430K	﹤0.01%	1810

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace's ELEV Position: Q3 2025 in Review

Marshall Wace sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 154,793 shares — an estimated $57.3K sold.

Marshall Wace first reported a position in ELEV in Q1 2024 and held it in 3 quarters. The position peaked at $681K in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Marshall Wace reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Marshall Wace sold 154,793 Elevation Oncology shares in Q3 2025, an estimated $57.3K.
Marshall Wace first reported a position in Elevation Oncology in Q1 2024 and held it in 3 quarters.
Marshall Wace's Elevation Oncology position peaked at $681K in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.